Global Nosebleeds Market, Treatment Type (Vasoconstrictors, Anesthetics, Antibiotic Ointments, Cauterizing Agents, Others), Route of Administration (Oral, Intranasal, Others), Indication (Posterior Epistaxis, Anterior Epistaxis), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Nosebleeds (epistaxis) is a disorder that causes sporadic nose bleeding in one or both nostrils. This clinical condition is commonly characterized as posterior epistaxis or anterior epistaxis based on where the bleeding begins. According to The New England Journal of Medicine, around 60% of people worldwide have had epistaxis at least once in their lives, with only 6% requiring medical treatment. Epistaxis is extremely common in children under the age of ten and in persons over the age of 35.
Data Bridge Market Research analyses that the nosebleeds market was valued at USD 183.93 million in 2021 and is expected to reach USD 275.92 million by 2029, registering a CAGR of 5.20% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Vasoconstrictors, Anesthetics, Antibiotic Ointments, Cauterizing Agents, Others), Route of Administration (Oral, Intranasal, Others), Indication (Posterior Epistaxis, Anterior Epistaxis), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Due to the general placement of the nose and the near proximity of blood vessels in the lining of your nose, nosebleeds (also known as epistaxis) are common. The doctor may cauterize the bleeding vessel or pack the nose to halt the bleeding if it does not cease on its own or when pressure is applied. Cauterization includes burning the vessel with a particular solution called silver nitrate or an electrical or thermal device to halt the bleeding. It may be beneficial to reduce or eliminate the use of blood thinners. It's also possible that blood pressure drugs will be required. Tranexamic (Lystedaâ), a blood clotting aid, may be prescribed.
Nosebleeds Market Dynamics
Drivers
- Rising incidences of hypertension
The rising incidences of hypertension will act as a major driver that will result in the expansion of the market's growth rate. Hypertension and epistaxis are two health disorders that are linked, therefore people with hypertension are more susceptible to epistaxis. Because nasal bleeding occurs when blood pressure levels are high, nosebleed is one of the primary symptoms of hypertension, and hypertension is one of the primary causes of epistaxis. Although epistaxis is linked to blood problems, hypertension is one of the underlying causes of spontaneous bleeding in the mucous membrane of the nose. According to the World Health Organization (WHO), hypertension is responsible for more than 12% of all fatalities globally, making it one of the main causes of death.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of nosebleeds market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, surging number of government initiatives to spread awareness and rising addiction of smoking will result in the expansion of nosebleeds market. Along with this, rising level of disposable income and rising prevalence of diabetes will enhance the market's growth rate.
Opportunities
- Rise in R & D activities
The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the nosebleeds market growth. The latest surgical procedures include endoscopic litigation of the sphenopaletine artery, maxillary artery litigation, and nasal cauterization. As a result of the introduction of innovative surgeries, the worldwide epistaxis market is changing dramatically. Furthermore, manufacturers are increasingly focusing their efforts on developing epistaxis solutions for the treatment of people with specific medical conditions such as asthma, pregnancy, diabetes, and cancer.
- Launch of innovative products
Manufacturers in the epistaxis devices market are heavily emphasizing expanding research and innovation spending to invent and develop new and novel epistaxis devices. Stryker, for instance, has a novel product called XeroGel, which is a unique blend of polyethylene glycol (PEG) and chitosan that provides patients with a comfortable post-operative experience. This is estimated to create opportunities for the nosebleeds market growth in coming years.
Moreover, the market's growth is fueled by investment for the development of advanced technologies and increase in the number of emerging markets. These factors will provide beneficial opportunities for the nosebleeds market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of nosebleeds market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the nosebleeds market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This nosebleeds market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nosebleeds market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Nosebleeds market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Nosebleeds Market Scope
The nosebleeds market is segmented on the basis of indication, treatment type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Vasoconstrictors
- Anesthetics
- Antibiotic Ointments
- Cauterizing Agents
- Others
Indication
- Posterior Epistaxis
- Anterior Epistaxis
Route of Administration
- Oral
- Intranasal
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Nosebleeds Market Regional Analysis/Insights
The nosebleeds market is analysed and market size insights and trends are provided by country, indication, treatment type, route of administration, end-users and distribution channel as referenced above.
The countries covered in the nosebleeds market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the nosebleeds market because of the rising healthcare expenditure and extreme weather conditions, which can lead to nose bleeding in this region. Additionally, growing focus of major key players in research and development activities for nosebleeds and rise in patient assistance programs will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow significantly during the forecast period of 2022-2029 due to presence of key market players in this region. Also, the development of healthcare infrastructure and large number of generic manufacturer will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Nosebleeds Market Share Analysis
The nosebleeds market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to nosebleeds market.
Some of the major players operating in the nosebleeds market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Lupin (India)
- Allergan (Ireland)
SKU-